Author: Bill Snyder
Sep. 27, 2012—The Chemical and Physical Biology Admissions (CPB-A) Program, an inter-departmental first-year graduate admissions program at Vanderbilt University, has been renamed the Quantitative and Chemical Biology (QCB) Program.
Sep. 21, 2012—Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.
Sep. 20, 2012—Hassane Mchaourab, Ph.D., professor of Molecular Physiology & Biophysics, Physics and Chemistry, has been named the new director of the Ph.D.-granting Chemical and Physical Biology (CPB) program at Vanderbilt University.
Sep. 13, 2012—R. Alto Charo, J.D., a nationally known bioethicist at the University of Wisconsin Law School in Madison, will deliver the first Flexner Discovery Lecture on Thursday, Sept. 20.
Sep. 10, 2012—The 2012 Vanderbilt Prize in Biomedical Science has been awarded to Yale University professor Joan Steitz, Ph.D., whose pioneering work has helped reveal and clarify the complexities of RNA and the roles that RNA molecules play in health and disease. The prize, established by Vanderbilt University School of Medicine in 2006, honors nationally and internationally...
Sep. 6, 2012—The first Chancellor’s Lecture of the academic year, entitled “Genomes, Hype and a Realistic Pathway to Personalized Medicine,” will be given Wednesday, Sept. 12, by Dan Roden, M.D., assistant vice chancellor for Personalized Medicine at Vanderbilt University.